Publications

Asakura TA, Chen Q, Nathan S, Tripathi P, and Swift,  RA. Improvement of the mass production of Nicosan™/XICKLE™, an herbal medicine that contains strong antisickling agents. Sickle Cell Disease Association of America, 36^th Annual Meeting (New Orleans, LA September 2008).

Asakura TA, Swift, RA and Chen Q NIPRISAN reduced the precentage of reversible sickled cells in the blood of 100% human Hb S mice and prolonged their survivial time to longer than one year . Sickle Cell Disease Association of America, 37^th Annual Meeting (Orlando, FL September 2009).

Awodgan AO, Wambebe C, Gamaniel K, Okogun JJ, Orisadipe AT and Akah PA. Acute and short-term toxicity of NIPRISAN in rats I: a biochemical study. J. Pharm. Res. Dev. 1:1 39-45 1996.

Cordeiro NJV, Oniyangi O Phytomedicines (medicines derived from plants) for sickle cell disease. http://www.cochrane.org/reviews/en/ab004448.htm

lGamaniel K, Amor S, Akah PA, Samuel BB, Kapur S, et. al. Pharmacological Profile of NIPRD 94/002/1-0: A Novel Herbal Antisickling Agent. J. Pharm. Res. Dev. 3:2 89-94 1998.

Iyamu EW, Turner EA, Asakura T. In vitro effects of NIPRISAN (Nix-0699): a naturally occurring, potent antisickling agent.  Br J Haematol. 118:1 337-43 2002.

Iyamu EW, Turner EA, Asakura T. Niprisan (Nix-0699) improves the survival rates of transgenic sickle cell mice under acute severe hypoxic conditions. Br J Haematol. 122:6 1001-8 2003.

Nathan S., Tripath P, Wu QL and Belanger FC Nicosan: A Phytomedicinal Treatment for Sickle Cell Disease In: African Natural Plant Products: New Discoveries and Challenges in Chemistry and Quality, Juliani, H.R.,  Simon, J.E.,Ho, C.T. (Eds). ACS Symposium Series, American Chemical Society: Washington, D.C., 2009.   

Swift RA, Nathan S, Tripathi P, Chen Q, and Asakura TA. Research preview on improving NICOSAN™/XICKLE™, a phyto-medicine for the treatment of Sickle Cell Disease. Sickle Cell Disease Association of America, 36^th Annual Meeting (New Orleans, LA September 2008).

Wambebe C, Barngboye EA, Badru BO, Khamofu H et. al. Efficacy of NIPRISAN in the Prophylactic Management of Patients with Sickle Cell Disease.  Cur. Treat. Res. 62:1 26-33 2001.

Wambebe C, Khamofu H, Momoh AF, Ekpeyong M, Audu BS et. al. Double-blind, placebo-controlled, randomized cross-over clinical trial of NIPRISAN in patients with Sickle Cell Disorder. Phytomedicine 5:4 252-61 2001.